Thermo Fisher reports 23 percent growth in Q1FY18

Thermo Fisher Scientific Inc. reported its financial results for the first quarter ended March 31, 2018. First quarter 2018 highlights include:

• First quarter revenue grew 23 percent to USD 5.85 billion versus USD 4.77 billion in 2017.
• First quarter GAAP diluted earnings per share (EPS) increased 2 percent to USD 1.43 versus USD 1.40 in the same quarter last year.
• First quarter adjusted EPS increased 20 percent to USD 2.50 versus USD 2.08 in the first quarter of 2017.
• Organic revenue growth was 7 percent; acquisitions increased revenue by 12 percent and currency translation increased revenue by 4 percent.
• Launched new products including Thermo Scientific Vanquish Duo UHPLC systems for pharma QA/QC, the Thermo Scientific Chromeleon XTR Laboratory Management System and the Ion GeneStudio S5 Series of next-generation sequencing instruments.
• Held first China-US Precision Medicine Summit in Beijing, convening more than 400 thought leaders across government, academia and industry to promote global collaboration in the prevention, diagnosis, and treatment of disease.
• Adjusted EPS, adjusted operating income, adjusted operating margin and free cash flow are non-GAAP measures that exclude certain items detailed later in this press release under the heading use of non-GAAP financial measures.

“We are pleased to start the year on a very strong note, with excellent revenue and earnings growth, which positions us to deliver another excellent year.”

Marc N Casper
President and CEO,
Thermo Fisher Scientific